Clinical characteristics of patients diagnosed with Guillain Barré Syndrome in three specialized institutions in the city of Medellín, 2015-2020.
DOI:
https://doi.org/10.31157/an.v28i3.446Keywords:
Guillain-Barre Syndrome, autoimmunity, Miller Fisher syndrome, viral diseases, autoimmune diseases of the nervous system, neurologyAbstract
INTRODUCTION: The Guillain-Barré syndrome (GBS) is an autoimmune disorder characterized by symmetrical weakness of both lower and upper limbs, impaired deep tendon reflexes, paresthesias, and myopathic changes. Serious cases can affect the respiratory bulbar musculature and lead to death. Despite an increase in Zika virus cases in Colombia, little is known about the disease's presentation or behavior after the epidemic.
METHODS: A cross-sectional descriptive study was conducted in three specialized institutions in Medellín to identify the clinical and sociodemographic characteristics of GBS patients. Between 2015 and 2020, medical records with the diagnosis code G61.0 were analyzed.
RESULTS: A total of 120 medical records were analyzed. The mean age of the patients was 50.29 +/- 20 years, 57.5% of them being men. The onset of the pathology was preceded by gastrointestinal and respiratory history in 55% of the patients. Among the patients, 45.83% had acute inflammatory demyelinating polyneuropathy, 21.67% had acute motor sensory axonal neuropathy, 24.17% had acute motor axonal neuropathy, and 7 had Miller Fisher syndrome. During the study time period, five patients died.
CONCLUSIONS: GBS diagnosis presents a decrease in the report after the Zika virus epidemic in Colombia, affects adults and older adults with typical manifestations of the disease.
References
Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain. 2018;141(10):2866–2877. doi:10.1093/brain/awy232 DOI: https://doi.org/10.1093/brain/awy232
Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain–Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671–683. doi:10.1038/s41582-019-0250-9 DOI: https://doi.org/10.1038/s41582-019-0250-9
Mahecha MP, Ojeda E, Vega DA, Sarmiento-Monroy JC, Anaya JM. Guillain–Barré syndrome in Colombia: where do we stand now? Immunol Res. 2017;65(1):72–81. doi:10.1007/s12026-016-8816-8 DOI: https://doi.org/10.1007/s12026-016-8816-8
Laman JD, Huizinga R, Boons GJ, Jacobs BC. Guillain-Barré syndrome: expanding the concept of molecular mimicry. Trends Immunol. 2022;43(4):296–308. doi:10.1016/j.it.2022.02.003 DOI: https://doi.org/10.1016/j.it.2022.02.003
Jacobs BC, Rothbarth PH, van der Meché FGA, et al. The spectrum of antecedent infections in Guillain-Barré syndrome. Neurology. 1998;51(4):1110–1115. doi:10.1212/WNL.51.4.1110 DOI: https://doi.org/10.1212/WNL.51.4.1110
Wanschitz J, Maier H, Lassmann H, Budka H, Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barré syndrome. Brain. 2003;126(9):2034–2042. doi:10.1093/brain/awg207 DOI: https://doi.org/10.1093/brain/awg207
Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49(6):712–720. doi:10.1002/ana.1012 DOI: https://doi.org/10.1002/ana.1012
González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barré Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol. 2013;13(1):95. doi:10.1186/1471-2377-13-95 DOI: https://doi.org/10.1186/1471-2377-13-95
Fokke C, Van Den Berg B, Drenthen J, Walgaard C, Van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(1):33–43. doi:10.1093/brain/awt285 DOI: https://doi.org/10.1093/brain/awt285
van der Meché FGA, Schmitz PIM. A Randomized Trial Comparing Intravenous Immune Globulin and Plasma Exchange in Guillain–Barré Syndrome. N Engl J Med. 1992;326(17):1123–1129. doi:10.1056/NEJM199204233261705 DOI: https://doi.org/10.1056/NEJM199204233261705
Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214–1228. doi:10.1016/S0140-6736(21)00517-1 DOI: https://doi.org/10.1016/S0140-6736(21)00517-1
Parra B, Lizarazo J, Jiménez-Arango JA, et al. Guillain–Barré Syndrome Associated with Zika Virus Infection in Colombia. N Engl J Med. 2016;375(16):1513–1523. doi:10.1056/nejmoa1605564 DOI: https://doi.org/10.1056/NEJMoa1605564
Salinas JL, Walteros DM, Styczynski A, et al. Zika virus disease-associated Guillain-Barré syndrome—Barranquilla, Colombia 2015–2016. J Neurol Sci. 2017;381:272–277. doi:10.1016/j.jns.2017.09.001 DOI: https://doi.org/10.1016/j.jns.2017.09.001
Méndez N, Oviedo-Pastrana M, Mattar S, Caicedo-Castro I, Arrieta G. Zika virus disease, microcephaly and Guillain-Barré syndrome in Colombia: Epidemiological situation during 21 months of the Zika virus outbreak, 2015-2017. Arch Public Heal. 2017;75(1):1–11. doi:10.1186/s13690-017-0233-5 DOI: https://doi.org/10.1186/s13690-017-0233-5
Anaya JM, Rodríguez Y, Monsalve DM, et al. A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. J Autoimmun. 2017;77:123–138. doi:10.1016/j.jaut.2016.12.007 DOI: https://doi.org/10.1016/j.jaut.2016.12.007
Sipilä JOT, Soilu-Hänninen M, Ruuskanen JO, Rautava P, Kytö V. Epidemiology of Guillain-Barré syndrome in Finland 2004-2014. J Peripher Nerv Syst. 2017;22(4):440–445. doi:10.1111/jns.12239 DOI: https://doi.org/10.1111/jns.12239
Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain–Barré syndrome in low-income and middle-income countries: challenges and prospects. Nat Rev Neurol. 2021;17(5):285–296. doi:10.1038/s41582-021-00467-y DOI: https://doi.org/10.1038/s41582-021-00467-y
Isaza S, Pérez A UC. Descripción de los casos de síndrome de Guillain Barré en el Hospital San Vicente de Paúl entre los años 2001 y 2005. Acta Neurol Colomb. 2009;25(3):123–129.
González P, García X, Guerra A, et al. Experiencia del síndrome de Guillain-Barré en una Unidad de Cuidados Intensivos neurológicos. Neurología. 2016;31(6):389–394. doi:10.1016/j.nrl.2014.09.004 DOI: https://doi.org/10.1016/j.nrl.2014.09.004
López-hernández JC, Galnares-olalde JA, Gutiérrez A, Estrada SA, García-grimshaw M, Vargas-cañas ES. Síndrome de Guillain-Barré en México : características clínicas y validación de los criterios de Brighton. Rev Neurol. 2022;74(8):258–264. doi:10.33588/rn.7408.2021437
Gómez Á, Díaz A, Carrión‐Penagos J, Reyes J, Reyes S. Clinical and electrophysiological characteristics of Guillain‐Barré syndrome in Colombia. J Peripher Nerv Syst. 2019;24(3):268–271. doi:10.1111/jns.12340 DOI: https://doi.org/10.1111/jns.12340
Al-Hakem H, Sindrup SH, Andersen H, et al. Guillain–Barré syndrome in Denmark: a population-based study on epidemiology, diagnosis and clinical severity. J Neurol. 2019;266(2):440–449. doi:10.1007/s00415-018-9151-x DOI: https://doi.org/10.1007/s00415-018-9151-x
Forsberg A, Press R, Holmqvist LW. Residual disability 10years after falling ill in Guillain–Barré syndrome: A prospective follow-up study. J Neurol Sci. 2012;317(1–2):74–79. doi:10.1016/j.jns.2012.02.026 DOI: https://doi.org/10.1016/j.jns.2012.02.026
Pollak TA, Lennox BR, Müller S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. The Lancet Psychiatry. 2020;7(1):93–108. doi:10.1016/S2215-0366(19)30290-1 DOI: https://doi.org/10.1016/S2215-0366(19)30290-1
Benedetti MD, Pugliatti M, D’’Alessandro R, et al. A Multicentric Prospective Incidence Study of Guillain-Barré Syndrome in Italy. The ITANG Study. Neuroepidemiology. 2015;45(2):90–99. doi:10.1159/000438752 DOI: https://doi.org/10.1159/000438752
Kobori S, Kubo T, Otani M, et al. Coexisting infectious diseases on admission as a risk factor for mechanical ventilation in patients with Guillaine-Barré syndrome. J Epidemiol. 2017;27(7):311–316. doi:10.1016/j.je.2016.07.003 DOI: https://doi.org/10.1016/j.je.2016.07.003
Delannoy A, Rudant J, Chaignot C, Bolgert F, Mikaeloff Y, Weill A. Guillain-Barré syndrome in France: a nationwide epidemiological analysis based on hospital discharge data (2008-2013). J Peripher Nerv Syst. 2017;22(1):51–58. doi:10.1111/jns.12202 DOI: https://doi.org/10.1111/jns.12202
Aragonès JM, Altimiras J, Alonso F, et al. Incidencia y características clínicas del síndrome de Guillain-Barré en la comarca de Osona (Barcelona, España) (2003-2016). Neurología. 2021;36(7):525–530. doi:10.1016/j.nrl.2018.03.021 DOI: https://doi.org/10.1016/j.nrl.2018.03.021
Walgaard C, Lingsma HF, Ruts L, Van Doorn PA, Steyerberg EW, Jacobs BC. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology. 2011;76(11):968–975. doi:10.1212/WNL.0b013e3182104407 DOI: https://doi.org/10.1212/WNL.0b013e3182104407
Márquez Rosales BA, Vargas Rodríguez LJ, Guerra Guerra LI. Caracterización del síndrome de Guillain-Barré en pacientes atendidos en un hospital en Colombia entre el año 2009 y el 2019. Neurol Argentina. 2021;(x x):1–7. doi:10.1016/j.neuarg.2021.10.003 DOI: https://doi.org/10.1016/j.neuarg.2021.10.003
Millán S, Díaz C, David Pardo DG, Castro Guzmán G. Clinical and neurophysiological characteristics of patients with Guillain‐Barré syndrome at Hospital Universitario San Ignacio, Bogotá, Colombia between 2009 and 2017. J Peripher Nerv Syst. 2019;24(3):272–275. doi:10.1111/jns.12345 DOI: https://doi.org/10.1111/jns.12345
Lynch RM, Mantus G, Encinales L, et al. Augmented Zika and Dengue Neutralizing Antibodies Are Associated With Guillain-Barré Syndrome. J Infect Dis. 2019;219(1):26–30. doi:10.1093/infdis/jiy466 DOI: https://doi.org/10.1093/infdis/jiy466
Charniga K, Cucunubá ZM, Walteros DM, et al. Descriptive analysis of surveillance data for Zika virus disease and Zika virus-associated neurological complications in Colombia, 2015–2017. Londono B, ed. PLoS One. 2021;16(6):e0252236. doi:10.1371/journal.pone.0252236 DOI: https://doi.org/10.1371/journal.pone.0252236
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
September 2022-present © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January-September 2022 © The authors. Open access articles under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. No commercial re-use is allowed.
January 2014-December 2021 © Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez. Open access articles under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
